SOHO 2025 | The evolution of treatment goals in CML: beyond survival outcomes
Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, discusses the evolution of treatment goals in chronic myeloid leukemia (CML), highlighting the shift from focusing on survival to incorporating quality of life and treatment discontinuation as key objectives. Dr Cortes emphasizes the need for ongoing research and development to address the remaining gaps in CML treatment. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The topic is interesting because as our treatment strategies or our availability of different treatments has evolved over time and our ability to monitor the disease, with more sensitive tools, and all that, the goals of therapy have changed, the patient’s goals have changed. So I’m going to try to review how the evolution has gone and how we integrate the different elements that we have, not only the different drugs, but also the different ways in which we now, for example, aim more and more towards better quality of life and treatment discontinuation, whereas in the past it was just better survival...
The topic is interesting because as our treatment strategies or our availability of different treatments has evolved over time and our ability to monitor the disease, with more sensitive tools, and all that, the goals of therapy have changed, the patient’s goals have changed. So I’m going to try to review how the evolution has gone and how we integrate the different elements that we have, not only the different drugs, but also the different ways in which we now, for example, aim more and more towards better quality of life and treatment discontinuation, whereas in the past it was just better survival. So because we have so many more tools and many more approaches, I think it is important to see how, and it’s interesting because what we have informs our algorithms and then our algorithms inform what else we need. So that’s kind of the discussion we’re going to have and see how we are, if we’re focusing on survival we’re done, if we’re focusing on the new needs we’re definitely not done and why we need additional studies, of course, additional drugs, additional concepts, additional strategies, on what to focus. I think it is very important to recognize that there are still many, many gaps that we haven’t covered in CML that we still need to focus on.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
